Naamidine A reveals a promising zinc-binding strategy for topical antifungal therapy
Fungal disease affects over a billion people worldwide. Naamidine A inhibits the growth of diverse fungal pathogens through an unknown mechanism. Here, we show that the supplementation of medium with excess zinc abolishes the antifungal activity of naamidine A. Furthermore, we highlight that naamidine A has <i>in vitro</i> activity against terbinafine-resistant <i>Trichophyton spp</i>. and <i>in vivo</i> efficacy in a mouse model of dermatomycosis caused by <i>T. mentagrophytes,</i> highlighting its therapeutic potential as a topical treatment.
Authors
- Emily Puumala (ORCID: https://orcid.org/0009-0008-3371-5877)
- Priya Uppuluri (ORCID: https://orcid.org/0000-0002-5889-054X)
- Luke J. Whitesell (ORCID: https://orcid.org/0000-0001-6445-5766)
- Leah E. Cowen (ORCID: https://orcid.org/0000-0001-5797-0110)
- Tanja Grkovic (ORCID: https://orcid.org/0000-0002-6537-3997)
- Barry R. O’Keefe (ORCID: https://orcid.org/0000-0003-0772-4856)
- Christopher C. Thornburg (ORCID: https://orcid.org/0000-0002-4657-6895)
- Sunna Nabeela (ORCID: https://orcid.org/0000-0002-8066-2199)
- Nicole Robbins
Institutions
- Leidos (United States) (US)
- Target (United States) (US)
- University of California, Los Angeles (US)
- University of Toronto (CA)
- Los Angeles Medical Center (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1128/aac.01194-24
- Citations
- 2
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- U.S. Department of Health and Human Services
- Canadian Institute for Advanced Research
- National Institutes of Health
- Canadian Institutes of Health Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- Moonshot Research and Development Program
- Cancer Moonshot